A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures
Start Date
12/15/2025
Completion Date
2/3/2028
Summary
This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine RAP-219 Long- term safety and open-label antiseizure activity in patients with Refractory Focal Epilepsy.
Detailed Description
This is a multi-center, open-label study to evaluate the long-term safety, tolerability, pharmacokinetics, pharmacodynamics and antiseizure activity of RAP-219 in adult participants with refractory focal seizures
Eligibility Criteria
Age Range: 18 years to 70 years
Interventions
RAP-219
Conditions
Locations
Consultants in Epilepsy and Neurology, PLLC
Boise, Idaho 83702
United States
Mayo Clinic
Rochester, Minnesota 55905
United States
NYU Langone Comprehensive Epilepsy Center
New York, New York 10016
United States
Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States
University of Pennsylvania - Department of Neurology
Philadelphia, Pennsylvania 19104
United States
Vanderbilt University Medical Center
Nashville, Tennessee 37232
United States
Baylor College of Medicine
Houston, Texas 770300
United States